Journal of Pharmaceutical and Biomedical Sciences

Severe Form of Primary Intestinal Lymphangiectasia in an One-Year-Old Child

Minira Bulegenova, Oleg Mustafin, Anna Makhneva, Aigul Bekisheva

Abstract


Primary intestinal lymphangiectasia (Waldmann syndrome) is a congenital abnormality of the lymphatic system in children – a disease that occurs infrequently. There are about 80 published descriptions of this pathology in infants. The main clinical manifestation of intestinal lymphangiectasia is a syndrome of malabsorption: diarrhoea, nausea, vomiting, abdominal pain and peripheral oedema. In some cases, steatorrhoea of varying severity occurs. Long lasting of the disease, no effect on the therapy leads to such complications as chylous ascites and chylothorax. This paper presents a clinical case of an early debut primary intestinal lymphangiectasia in a 6-month-old child, complicated by development of concomitant immunodeficiency. The final diagnosis was set after the histological examination of biopsy material in jejunum. Substitution therapy with albumin had no positive effect. Because of the constant hypoproteinemia that had not been corrected with either albumin or ongoing corticosteroid therapy, it was decided to start the sandostatin therapy. With improvement in the patient’s condition, he was transferred from intensive care to the department of somatic pathology. Transfusions of albumin have been cancelled. The protein level increased up to 53 g/l, swelling disappeared, but general sponginess of the tissue remained. The patient was discharged from the hospital with recommendations to continue the combined therapy including sandostatin and compulsory monitoring of the concentration of immunoglobulins.

Keywords


intestinal lymphangiectasia, malabsorption syndrome, hypoproteinemia, immunodeficiency, sandostatin

Full Text:

References


Braamskamp MJ, Dolman KM, Tabbers MM. Clinical practice. Protein losing enteropathy in children. Eur J Pediatr. 2010;169:1179–85.

Zlatkina AR. Chronic enteropathy: pathogenesis and treatment strategy. Quality of the life. Moscow: Meditsina; 2004;5.

Umar SB, DiBaise JK. Protein-losing enteropathy: case illustrations and clinical review. Am J Gastroenterol. 2010;105(1):43–49.

Proujansky R. Protein-losing enteropathy. In: Walker WA, Goulet OJ, Kleinman RE, Sanderson IR, Sherman PM, Shneider BL, editors. Pediatric gastrointestinal disease. Ontario: BC Decker

Inc; 2004: 194–202.

Greenwald D. Protein-losing gastroenteropathy. In: Feldman M, Friedman LS, Brandt LJ, Sleisinger MH, editors. Gastrointestinal and liver disease. Philadelphia: Saunders; 2006.

Vignes S, Bellanger J. Primary intestinal lymphangiectasia (Waldmann’s disease). Orphanet J Rare Dis. 2008;22:3–5.

Suresh N, Ganesh R, Sankar J, Sathiyasekaran M. Primary intestinal lymphangiectasia. Indian Pediatr. 2009;46(10):903–6.

Hokari R, Kitagawa N, Watanabe C, Komoto S, Kurihara C, Okada Y, et al. Changes in regulatory molecules for lymphangiogenesis in intestinal lymphangiectasia with enteric protein loss. J Gastroenterol Hepatol. 2008;23:e88–e95.

Klempa I. A therapeutic trial of somatostatin (Serono) in surgery of the pancreas. Data on file. 1981.

???????? ??, ???????? ??. ????????? ? ????????????? ?????????????????. ???. 2003; 3.

http://www.pharm-sintez.ru/ links/ContOk.htm

Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28:836–46.

Lam JC, Aters S, Tobias JD. Initial experience with octreotide in the pediatric population. Am J Ther. 2001;8:409–15.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 Journal of Pharmaceutical and Biomedical Sciences

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.